65 results about "Reduced serum uric acid" patented technology

The invention discloses a rhizoma smilacis glabrae leavening and a preparation method and application thereof in hyperuricemia, and the scheme is as follows: inoculating a lactobacillus fermentation seed solution into a rhizoma smilacis glabrae traditional Chinese medicine stock solution, fermenting for 48-72 hours at 37 DEG C, and freeze-drying to obtain the rhizoma smilacis glabrae leavening; the lactobacillus brevis fermentation seed liquid is prepared by fermenting lactobacillus brevis YM 1301 and lactobacillus plantarum CICC24202, and the lactobacillus brevis YM 1301 and the lactobacillus plantarum CICC24202 are fermented; the lactobacillus fermentation seed liquid accounts for 6-10% of the volume of the rhizoma smilacis glabrae traditional Chinese medicine Results show that after the rhizoma smilacis glabrae is fermented, the contents of total flavone and total polyphenol are increased, and the polysaccharide content is reduced; the rhizoma smilacis glabrae leavening can significantly reduce serum uric acid, urea nitrogen and creatinine levels of HUA rats; the kidney injury caused by hyperuricemia is improved; the increase of inflammatory cytokines such as IL-1beta and TNF-alpha in serum is reduced, and the curative effect is superior to that of unfermented rhizoma smilacis glabrae; the mechanism of reducing uric acid may be by inhibiting the activity of xanthine oxidase in HUA rats and increasing the excretion of uric acid in excrement. The invention provides a solid theoretical reference basis for developing safe and effective uric acid-reducing traditional Chinese medicine large-scale health products.

The preparation method comprises the following steps: centrifuging an activated culture solution of animal bifidobacterium subsp. Lactis HNU212 to remove a supernatant, washing with 0.9% normal saline, adjusting the strain concentration to 1 * 10 < 9 > CFU / mL, and inactivating at 90 DEG C for 15 minutes, thereby obtaining the thermal inactivation bifidobacterium subsp. Lactis metagen. The invention also provides a preparation method of the thermal inactivation bifidobacterium subsp. Lactis metagen, and the preparation method of the thermal inactivation bifidobacterium subsp. Lactis metagen comprises the following steps of: preparing the thermal inactivation bifidobacterium subsp. Lactis metagen and the preparation method of the thermal inactivation bifidobacterium subsp. Lactis metagen. When applied to an HUA animal model, the thermal inactivation substance bifidobacterium subsp. Lactis metaplasm prepared by the invention can effectively reduce the serum uric acid level, relieve kidney and intestinal injury and regulate host intestinal flora, and has the effect of relieving and treating HUA.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The present invention relates to a uric acid-lowering probiotic complex and its application. The probiotic complex comprises Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024; wherein Lactobacillus reuteri FPH2951 is classified as Lactobacillus reuteri and has a deposit number of GDMCC No. 62946; and Bifidobacterium breve FPHC4024 is classified as Bifidobacterium breve and has a deposit number of GDMCC No. 62945. The probiotic complex of the present invention can significantly reduce serum uric acid (UA), creatinine (Cr), and blood urea nitrogen (BUN) levels and increase urine excretion of creatinine (Cr) and blood urea nitrogen (BUN) through the synergistic effect of Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024, and has broad application prospects.

The invention discloses a traditional Chinese medicine and probiotic composition and application thereof, and belongs to the technical field of medicines. The composition is prepared from a traditional Chinese medicine extract and lactobacillus brevis DMU22441 (the preservation number is CGMCC No.65301), wherein the traditional Chinese medicine extract is prepared from fructus gardeniae, rhizoma phragmitis and flos sophorae according to the mass ratio of 1: 1: 1. The traditional Chinese medicine extract is prepared through an ethanol extraction method, and the viable count of probiotics is 10 < 9 > CFU / day. According to the composition, through a three-in-one synergistic mechanism of inhibiting synthesis, promoting excretion and regulating flora, the serum uric acid level is remarkably reduced, renal function impairment is improved, and intestinal flora imbalance is regulated. The invention provides an efficient and safe multi-target solution for the treatment of hyperuricemia and complications thereof, and has significant clinical application value.

The invention belongs to the field of biological medicine, and particularly relates to application of urolithin D in preparation of medicine for relieving hyperuricemia. It is found for the first time that the urolithin D can significantly reduce the level of serum uric acid, improve the expression disorder of a kidney urate transporter, efficiently relieve or treat hyperuricemia and related diseases thereof, and relieve kidney injury and fibrosis; and the compound can be used for preparing medicines for treating hyperuricemia and related diseases, is low in cost and good in safety, and has a wide application prospect.

The present invention relates to the field of Chinese medicinal materials, and in particular to a Chinese medicine composition, a medicine, and a preparation method and application thereof for treating hyperuricemia with hyperlipidemia. The Chinese medicine composition and medicine provided by the present invention can intervene in the treatment of asymptomatic hyperuricemia combined with hyperlipidemia, and compared with traditional uric acid-lowering drugs (febuxostat), serum uric acid can be quickly reduced, and the uric acid level can be basically controlled within a normal range. No gout symptoms are found in patients within 6 months of treatment, and complications such as hypertension, hyperglycemia, and cardiovascular and cerebrovascular diseases can be significantly reduced, and the quality of life of patients can be improved; it can also overcome the technical deficiencies of uric acid-lowering drugs, such as many adverse reactions, difficult to sustain therapeutic effects, and limited applicable populations, and has the advantages of small side effects, long-lasting efficacy, and multiple drug targets.

The invention belongs to the technical field of biological medicines, and particularly relates to a cordyceps sobolifera fermentation extract for reducing uric acid as well as a preparation method and application of the cordyceps sobolifera fermentation extract. The method comprises the following steps: concentrating cordyceps sobolifera fungus fermentation liquor, then leaching with ethanol, concentrating leaching liquor, then sequentially extracting with n-butyl alcohol, ethyl acetate and petroleum ether, and concentrating extracts to respectively obtain an n-butyl alcohol extraction part, an ethyl acetate extraction part, a petroleum ether extraction part and a residual part, the obtained petroleum ether extract is the cordyceps sobolifera fermentation extract for reducing uric acid. The cordyceps sobolifera fermentation extract disclosed by the invention has the effects of remarkably relieving kidney injury of a mouse with hyperuricemia and reducing serum uric acid of the mouse with hyperuricemia. As a novel natural uric acid-reducing active substance, the cordyceps sobolifera fermentation extract disclosed by the invention can be applied to the fields of health foods and medicines, and has good development and application values.

The invention discloses screening and application of salt-resistant lactobacillus plantarum with multiple uric acid reducing functions. Samples are screened and collected in soil, sauced beans, fermented flour paste, fresh milk, pickled vegetables and the like, a strain obtained through screening is identified as Lactobacillus plantarum WQ47 and is named as Lactobacillus plantarum WQ47, the strain has high inosine and guanosine degradation capacity, the degradation rate is 99.9% or above, the degradation rate is 99.0% or above, and therefore the serum uric acid level can be effectively reduced. Besides, the strain WQ47 is cultured in an MRS lactic acid bacteria culture medium to a fermentation supernatant, a bacterial suspension and a cell-free extract in the middle and later periods of logarithmic growth, the xanthine oxidase inhibition rates are 44.9%, 33.4% and 62.8% respectively, uric acid generation can be effectively inhibited, purine generation can be reduced by degrading inosine and guanosine and inhibiting the activity of xanthine oxidase, and the strain WQ47 can be used for preparing a new strain for preventing and treating uric acid generation. The traditional Chinese medicines jointly achieve the effects of relieving and treating the hyperuricemia. Moreover, the strain WQ47 screened by the invention can well survive in an environment with high content of salt (NaCl) of 20% (mass fraction), can be widely applied to fermented food, pickled food, functional food and the like, and has a better application effect on preventing, relieving and treating hyperuricemia, gout and complications of the hyperuricemia and the gout.

The application discloses application of white ginseng mushroom in preparation of a medicine for treating hyperuricemia, and belongs to the technical field of deep processing of edible mushrooms. The white ginseng mushroom is vacuum freeze-dried, ground into powder, other traditional Chinese medicine ingredients are extracted, concentrated, and spray-dried into powder; the white ginseng mushroom powder is mixed with sodium carboxymethyl cellulose and guar gum solution to form a mushroom suspension colloid, the microcapsules are collected after being dropped into a calcium-containing aqueous solution; the microcapsules are immersed in a high polymer compound solution for treatment, finally mixed with a stabilizer paste, and then filled after being treated by a high-pressure homogenizer and sterilized. Compared with the prior art, the medicine has good stability in simulated gastric juice, can be quickly released in simulated intestinal juice, significantly improves the bioavailability and curative effect of the medicine, can effectively reduce the serum uric acid level, improve liver and kidney functions, and regulate the intestinal flora structure, and has a significant uric acid-lowering effect and multi-target synergistic effect.

The invention provides a traditional Chinese medicine preparation for dispelling wind and eliminating dampness and application, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of honeysuckle stem, spatholobus stem, silkworm excrement, gentian, safflower, peach kernel, ash bark, arisaema cum bile, medicated leaven and honeycomb; the traditional Chinese medicine preparation can remarkably reduce the ankle joint swelling degree of an acute gouty arthritis model rat, reduce the expression level of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in serum and reduce the content of uric acid, creatinine and XOD in the serum, so that the effects of resisting inflammation, easing pain and reducing blood uric acid are achieved; clinical test results show that the traditional Chinese medicine preparation can relieve the pain degree of a patient, reduce the levels of inflammation-related factors TNF-alpha and IL-1beta in knee joint synovial fluid of the patient, reduce inflammation indexes WBC, ESR and CRP in serum, relieve the inflammatory reaction of the body of the patient, reduce the occurrence rate of adverse reactions, and improve the curative effect of the patient. A novel traditional Chinese medicine preparation with high safety and good curative effect is provided for treatment of acute gout.

The invention discloses application of schizophyllumcommuneh in preparation of a medicine for treating hyperuricemia, and belongs to the technical field of deep processing of edible mushrooms. Schizophyllumcommuneh is subjected to vacuum freeze drying and then ground into powder, and other traditional Chinese medicine components are subjected to extraction, concentration and spray drying to form powder; schizophyllumcommuneh powder is mixed with sodium carboxymethyl cellulose and a guar gum solution to form bacterial suspension colloid, the bacterial suspension colloid is dropped into a calcium-containing aqueous solution to be treated, and then microcapsules are collected; immersing the microcapsules into a high-molecular compound solution for treatment, finally mixing with stabilizer mucilage, treating by a high-pressure homogenizer, sterilizing and filling. Compared with the prior art, the medicine disclosed by the invention has good stability in simulated gastric juice and can be quickly released in simulated intestinal juice, the bioavailability and curative effect of the medicine are remarkably improved, the serum uric acid level can be effectively reduced, the liver and kidney functions can be improved, the intestinal flora structure can be adjusted, and the medicine has a remarkable uric acid reducing effect and a multi-target synergistic effect.

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The preparation method of the traditional Chinese medicine composition comprises the following steps: mixing ganoderma lucidum spore powder and idesia polycarpa fruit powder according to a mass part ratio of (10-90): (90-10), extracting by using a supercritical CO2 fluid extraction technology to obtain an extract phase, then carrying out decompression analysis to precipitate an extract, and drying to obtain traditional Chinese medicine composition powder. The invention provides the traditional Chinese medicine composition compounded by the ganoderma lucidum spore oil and the idesia oil, and cell experiments and animal experiments prove that the traditional Chinese medicine composition can remarkably inhibit uric acid synthesis and reabsorption, so that the level of serum uric acid is reduced, renal function impairment caused by hyperuricemia is improved, and the curative effect is improved. The compound can be used as a functional raw material for preparing a product for treating hyperuricemia or improving kidney injury caused by hyperuricemia; the raw materials are easy to obtain, the cost is low, the safety is high, and good development and application values are achieved.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and a preparation and application thereof. A compatibility system of monarch, minister, assistant and guide is adopted, rhizoma atractylodis, semen coicis and cortex phellodendri are taken as monarch drugs, polygonum cuspidatum, centella asiatica and fructus kochiae are taken as minister drugs, prepared rheum officinale, radix achyranthis bidentatae and caulis spatholobi are taken as guide drugs, gynostemma pentaphyllum, radix paeoniae alba and rhizoma polygonati are taken as adjuvant drugs, the medicinal materials are compounded according to a specific mass ratio, and the mass ratio of the monarch drugs to the minister drugs to the adjuvant drugs to the guide drugs is (50-80): (50-80): (30-55): (35-70). The traditional Chinese medicine composition provided by the invention can remarkably reduce the levels of blood uric acid, serum creatinine and urea nitrogen, reduce urine protein excretion and improve inflammation, a hypercoagulation state and lipid metabolism disorder, the total effective rate reaches 90%, the adverse reaction is slight, and the recurrence rate is low.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

The present invention discloses the combined use of scopolamine and hyoscyamine in the preparation of a drug for preventing or / and treating hyperuricemia. The combined use has an excellent synergistic effect, can significantly reduce the levels of serum uric acid, creatinine, and urea nitrogen, reduce the reabsorption of uric acid, creatinine, and urea nitrogen in urine by the kidney, and promote the excretion of the three, has significant anti-hyperuricemia activity, and has a protective effect on the kidney; it can also significantly reduce the generation of inflammatory factors, effectively improve the symptoms of joint swelling in gouty arthritis, and has clinical application value and development prospects.

A strain 44XB capable of producing urate oxidase and a use thereof, relating to the technical field of microorganisms and medicines. A strain 44XB capable of producing urate oxidase is preserved in the Korean Collection for Type Cultures (KCTC), with the preservation number: KCTC 43631, the preservation date: 26 September 2023, the preservation address: 181 lpsin-gil. Jeongeup-si, Jeonbuk 56212, South Korea, and the classification name: Ornithinibacillus sp. A use of the strain 44XB in preparation of drugs for treating hyperuricemia and gout. The strain 44XB can produce highly active urate oxidase, and can be used for microecological therapy of hyperuricemia to reduce serum uric acid in hyperuricemia, and thus has the potential to be used in microecological treatment of hyperuricemia and gout.

The invention discloses an application of sanguisorba officinalis sapogenin in preparation of a medicine for treating gout. Compared with the prior art, it is found for the first time that sanguisorba sapogenin can treat gout, especially acute gouty arthritis. Animal research proves that the sanguisorba sapogenin can remarkably relieve joint swelling and tissue damage caused by acute gouty arthritis by inhibiting release of inflammatory factors such as IL-1beta and TNF-alpha. Meanwhile, the sanguisorba sapogenin can also remarkably reduce the level of serum uric acid, and also has a certain treatment effect on gout in a remission stage and a chronic stage. Therefore, the sanguisorba officinalis sapogenin can be used for treating gout and has the potential and prospect of being prepared into the anti-gout medicine.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition, a method for reducing the serum uric acid level of a gout patient and application of topiromilast to preparation of a medicine for treating hyperuricemia / gout with hyperuricemia. The medicine is continuously administered according to the following dosage scheme: the initial dosage is 40-80mg / day, and the duration period is 2-4 weeks; the first adjusting dosage is 120-160mg / day, and the duration period is 2-4 weeks; the maximum dose is 160-320 mg / day, and the dose lasts for at least 8 weeks. According to the pharmaceutical composition, high-efficiency treatment of Chinese patients with hyperuricemia / gout is realized through a staged dosage increasing scheme, and renal function impairment is improved. The invention further provides a method for reducing the serum uric acid level of gout patients, continuous administration is carried out according to the dosage scheme, and the topiromilast is applied to preparation of the medicine for treating hyperuricemia / gout with hyperuricemia and is suitable for people with renal insufficiency.

The invention discloses application of lactobacillus delbrueckii JNL0010 in preparation of uric acid lowering drugs, and belongs to the technical field of microorganisms. The lactobacillus delbrueckii JNL0010 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No. 3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No. 31042. Animal experiment results show that the lactobacillus delbrueckii JNL0010 can significantly reduce the blood uric acid level of a hyperuricemia model mouse and relieve the kidney inflammation level, and shows huge application value. The lactobacillus delbrueckii JNL0010 not only can degrade purine and nucleoside and reduce serum uric acid, but also has a certain protection effect on kidneys, and compared with drugs, the lactobacillus delbrueckii JNL0010 is higher in safety, small in side effect and wide in market prospect.

The present application belongs to the technical field of bioactive peptides, functional food and biological medicine, and particularly relates to a marine fish-derived xanthine oxidase inhibiting heptapeptide NPLVTPP and its application in reducing uric acid. The present application discloses a marine fish-derived heptapeptide NPLVTPP with xanthine oxidase inhibiting activity, and the amino acid sequence of the heptapeptide is Asn-Pro-Leu-Val-Thr-Pro-Pro. The heptapeptide can be prepared by solid-phase chemical synthesis or marine fish protein enzymatic separation and purification, can significantly inhibit xanthine oxidase activity, reduce uric acid generation, can effectively reduce serum uric acid level in a hyperuricemia animal model, and can improve high uric acid related kidney function damage. The present application also protects the application of the heptapeptide in preparing xanthine oxidase inhibitors, uric acid reducing products, products for preventing or improving hyperuricemia and kidney damage, and a medicine, food or nutritional composition containing the heptapeptide. The polypeptide sequence of the present application is clear, the target is clear, the in vivo and in vitro efficacy is clear, the source is safe, and the polypeptide can be used in the fields of functional food and biological medicine.

The invention relates to application of mannitol in preparation of drugs for reducing uric acid and / or preventing and treating gout kidney. The mass volume percentage of mannitol is 2-5%, and the mannitol in the concentration range can reduce the serum uric acid level by increasing urine uric acid excretion, reduce the uric acid content of the kidney tissue of a gout patient and reduce the serum urea nitrogen and creatinine content at the same time, so that the kidney tissue is protected. The invention further provides a pharmaceutical composition for reducing uric acid and / or preventing and treating gout kidney, which comprises the following components in percentage by mass volume: 2-5% of mannitol and 0.45-0.9% of sodium chloride. The invention provides new application of mannitol, the mannitol has dual effects of reducing the blood uric acid level and protecting the renal function, and a new treatment choice is provided for gout and gout kidney patients.

The invention provides a mint extract and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine extracts.The preparation method comprises the following steps that mint powder and an ethanol solution are mixed, treated at 45-55 DEG C for 50-70 min and then subjected to ultrasonic extraction 1-5 times, and the mint extract is obtained; the mass volume ratio of the mint powder to the ethanol solution is 1g: (25-35) mL; the temperature of the ultrasonic extraction is 45-55 DEG C, the power of the ultrasonic extraction is 650-750W, and the time of each ultrasonic extraction is 30-50 minutes. The mint extract provided by the invention can significantly reduce serum uric acid, creatinine and urea nitrogen levels of HUA mice; kidney injury caused by hyperuricemia is improved, and the uric acid level of an organism is reduced by inhibiting the activity of xanthine oxidase in serum and liver.

The invention discloses an application of Kluyveromyces marxianus metabolite in preparation of drugs for reducing uric acid, protecting kidney and protecting intestinal tracts, and belongs to the technical field of medicines. The invention provides an oral composition / preparation which takes a Kluyveromyces marxianus fermentation metabolite as an effective component, and by inhibiting the activity of a purine metabolism key enzyme, regulating a kidney / intestinal uric acid transporter and remodeling the intestinal microecology, the effects of reducing uric acid and synchronously protecting the kidney and the intestine are realized, and the problems of single target spot, toxic and side effects, limitation on long-term medication and the like of the existing medicine are solved. The metabolite can significantly reduce serum uric acid, can protect kidney and intestinal functions, and realizes multiple effects of reducing uric acid, protecting kidney and protecting intestines. Compared with a single effect of an existing medicine, the kluyveromyces marxianus metabolite shows a more comprehensive treatment effect through regulation of intestinal flora, inhibition of xanthine oxidase and regulation and control of uric acid transporter.

The invention provides a roxburgh rose source intelligent delivery system and a preparation method and application thereof. The system is formed by self-assembling roxburgh rose endogenous components through physical field programming induction, and simultaneously meets the following requirements: (1) the molar ratio of Cu < 2 + > to Mn < 2 + > is (1: 5.5)-(1: 6.5), and the molar ratio of Cu < 2 + > to Sr < 2 + > is (1: 0.45)-(1: 0.51); (2) the Zeta potential is-5 mV to + 5 mV, and the conductivity is lt; 10 S / cm; (3) a release rate lt in simulated gastric juice; the release rate gt in simulated intestinal juice within 2 hours is 10%; 80%; and (4) in terms of solids, single administration MTD is greater than or equal to 5.0 g / kg. The system has nearly neutral Zeta potential and extremely low conductivity, keeps stable in long-term storage, can synergistically reduce serum uric acid, transaminase and blood sugar, and has a kidney protection effect while efficiently reducing uric acid. The invention further provides a green preparation method of the system and multi-field application of the system.

The invention relates to lalang grass rhizome polysaccharide for reducing uric acid as well as a preparation method and application thereof, and relates to the field of medicines. By reducing the activity of xanthine oxidase, increasing the expression of OAT1 and OAT3 proteins in the kidney, regulating and controlling the activity of antioxidant enzymes in the body, inhibiting the release of inflammatory factors, inhibiting the generation of uric acid and reducing the level of serum uric acid, the lalang grass rhizome polysaccharide has a good treatment effect on hyperuricemia and can effectively delay the renal lesion process.

The invention relates to the technical field of microorganisms and biological medicines, in particular to triple probiotics as well as a preparation method and application thereof, and the triple probiotics comprise at least one probiotic of bacillus, lactobacillus acidophilus and bifidobacterium longum. The triple probiotics provided by the invention form an'oxygen consumption-enzyme production-acid production 'synergistic chain, and through synergistic degradation of uric acid, inhibition of excessive growth of conditioned pathogens and enhancement of intestinal barrier functions, the blood uric acid level of patients with asymptomatic hyperuricemia is reduced, the alpha-diversity of intestinal tracts is improved, the abundance of butyric acid producing bacteria is improved, and the content of the butyric acid producing bacteria is improved. The ratio of escherichia coli to shigella is reduced; sIBO is effectively relieved or reversed, and digestive tract symptoms such as abdominal distension and exhaust are reduced. In addition, the triple probiotics avoid liver and kidney toxicity caused by chemical drugs, and are suitable for long-term administration.

The invention relates to a traditional Chinese medicine composition with an effect of reducing uric acid as well as a preparation method and application of the traditional Chinese medicine composition, which can effectively solve the problems of large toxic and side effects, poor safety after long-term use and low patient tolerance of the existing uric acid reducing medicine. The compound traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 1 to 20 parts of flos chrysanthemi, 1 to 10 parts of radix puerariae, 1 to 8 parts of folium mori, 1 to 8 parts of herba taraxaci, 1 to 10 parts of herba cichorii, 1 to 5 parts of herba pogostemonis, 1 to 5 parts of bulbus lilii, 1 to 5 parts of orange peel, 0.1 to 2 parts of radix ginseng and 0.1 to 2 parts of cordyceps militaris peptide. The effects of remarkably reducing the serum uric acid level, regulating the URAT1 protein expression of the kidney and reducing uric acid reabsorption are achieved, so that the hyperuricemia and related complications thereof are effectively prevented and treated.

The invention relates to the technical field of traditional Chinese medicine plant extract compositions, in particular to a herbal tea composition for preventing and treating gout and a preparation method and application thereof.The herbal tea composition is prepared from, by weight, 8-12 parts of folium cortex eucommiae, 40-50 parts of amaranthus spinosus, 8-15 parts of pawpaw and 10-15 parts of raw coix seeds. The folium cortex eucommiae, the amaranthus spinosus, the pawpaw and the raw semen coicis in the composition disclosed by the invention have a synergistic effect on clearing away heat and toxic materials, inducing diuresis, expelling turbidity, clearing damp, activating collaterals, protecting kidney and tonifying spleen, and jointly act on uric acid generation and excretion links, so that the overall effect of reducing the serum uric acid level of the composition is remarkably improved; and the composition can effectively relieve red, swollen, hot, painful and other symptoms of gouty joints. The composition mainly benefits from the anti-inflammatory activity of amaranthus spinosus, the tendon relaxing and collateral activating effects of pawpaw, the dampness excreting and joint benefiting effects of raw coix seeds and the overall anti-inflammatory and detumescence effects of the composition, and important symptomatic treatment support is provided for gout patients.